Bioventus (BVS) Competitors

Enovis (NYSE:ENOV) and Bioventus (NYSE:BVS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, community ranking, media sentiment, valuation, profitability and analyst recommendations.

Do analysts rate ENOV or BVS?

Enovis currently has a consensus target price of $58.00, suggesting a potential upside of 74.09%. Bioventus has a consensus target price of $14.33, suggesting a potential upside of 111.09%. Given Bioventus' higher possible upside, analysts clearly believe Bioventus is more favorable than Enovis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Bioventus	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Does the MarketBeat Community prefer ENOV or BVS?

Enovis received 4 more outperform votes than Bioventus when rated by MarketBeat users. Likewise, 66.04% of users gave Enovis an outperform vote while only 62.00% of users gave Bioventus an outperform vote.

Company	Underperform	Outperform
Enovis	Outperform Votes 35 66.04%	Underperform Votes 18 33.96%
Bioventus	Outperform Votes 31 62.00%	Underperform Votes 19 38.00%

Do insiders and institutionals hold more shares of ENOV or BVS?

98.4% of Enovis shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 2.7% of Enovis shares are held by insiders. Comparatively, 32.9% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media prefer ENOV or BVS?

In the previous week, Enovis had 6 more articles in the media than Bioventus. MarketBeat recorded 9 mentions for Enovis and 3 mentions for Bioventus. Bioventus' average media sentiment score of 1.37 beat Enovis' score of 1.00 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ENOV or BVS more profitable?

Enovis has a net margin of -5.95% compared to Bioventus' net margin of -7.11%. Bioventus' return on equity of 15.61% beat Enovis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-5.95%	4.39%	2.80%
Bioventus	-7.11%	15.61%	4.01%

Which has preferable valuation & earnings, ENOV or BVS?

Enovis has higher revenue and earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.15B	0.89	-$33.26M	-$13.95	-2.39
Bioventus	$567.70M	0.98	-$156.23M	-$0.48	-14.15

Which has more risk and volatility, ENOV or BVS?

Enovis has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.

Summary

Enovis beats Bioventus on 10 of the 18 factors compared between the two stocks.